

INDEX

- acamprosate 240–1
acute depression 99–109
acute mania 90–9
ADHD *see* attention deficit/hyperactivity disorder
age factors 57
agitation 21
agranulocytosis 35, 91
akathisia 25–6, 73
alcohol 129–30, 216–17, 223–30, 238–41, 251
allergic effects 75
alprazolam 132, 134, 138, 145–6, 153, 218
Alzheimer's disease 199–213
amantadine 26, 202
amisulpride 11, 16, 24, 30
amitriptyline 42, 45, 143, 249
amoxapine 45
amphetamines 22–3, 175–98, 219–20
anesthesia 38
anorexia nervosa 51, 193
antacids interactions 38
anticholinergic effects 70–1
anticonvulsants
 acute depression 99–103, 105, 108–9
 acute mania 91–2, 94–7
 anxiety 135, 138–9, 147
 drug interactions 36–7, 120–3
 indications 83, 90
 pharmacology 86–9
 sedative–hypnotic agents 166
 side effects 116–18, 124–5
antidepressants 41–80
 acute depression 99–102, 105
 acute period 63
 anxiety 129, 131–4, 139–45, 149
 attention deficit/hyperactivity disorder 181–2, 194
 childhood disorders 52
 combination therapies 19–20, 64–6
 continuation period 67
 discontinuation 69
 dosages 58–61
 drug interactions 36, 76–9
 drug monitoring 58, 62
 drug selection 55–76
 early period 62–3
 indications 49–55
 initiation of treatment 58
 maintenance period 67–9
 pharmacology 41–9

- antidepressants (*Continued*)
- predictors of poor response 57
 - pregnancy 57
 - recommendations 80
 - responsiveness 63–7
 - sedative–hypnotic agents 165
 - side effects 41, 43, 58, 62, 69–76, 149–51
 - substance abuse 241, 249–51
 - suicidality 74–5
- antiepileptics 196
- antihistamines 158, 165
- antipsychotics 1–39
- agitation 21
 - anxiety 135, 139, 147–8
 - bipolar disorder 19
 - clinical profiles 15–19
 - combination therapies 8–10, 12, 19–20
 - delirium 20
 - delusional disorder 20
 - dementia 21
 - developmental disorders 21–2
 - dosages 5–6, 8–12
 - drug interactions 36–9, 76–8, 123
 - drug selection 7–23
 - drug switching 12–13
 - Huntington's disease 22
 - indications 4–7
 - initiation of treatment 8–12
 - maintenance treatment 13–14
 - major depression 19–20
 - mental retardation 21–2
 - mood stabilizers 94, 105, 109, 118–19, 123
 - pharmacology 1–4
 - pregnancy 38–9
 - psychosis 19–20, 21
 - schizoaffective disorder 15
 - schizophrenia 1, 4, 7–19
 - side effects 1–3, 8–10, 14, 18, 20–36, 118–19, 125
 - substance abuse 241, 250–1
 - substance-induced psychoses 22–3
 - Tourette's disorder 22
 - treatment evaluation 12–13
 - treatment resistance 14–15
 - violent patients 15
 - see also* atypical antipsychotics
- anxiety 53, 58, 226
- anxiolytics 129–54
- combination therapies 148
 - contraindications 152–3
 - dosages 148–50
 - drug interactions 136, 151–2
 - drug selection 148–50
 - indications 139–48
 - initiation of treatment 148–50
 - mood stabilizers 93–4
 - pharmacology 131–9
 - pregnancy 152
 - side effects 136, 142, 149
 - special precautions 152–3
- aripiprazole
- anxiety 135
 - bipolar disorder 19
 - costs 6
 - dementia 21
 - drug interactions 36–8
 - mood stabilizers 84, 87, 92, 98, 101
 - pharmacology 1–4
 - schizophrenia 7–11, 16
 - side effects 24–5, 28, 30
- atomoxetine 43, 175–7, 179, 182–5, 189–90, 192, 196

- attention deficit/hyperactivity disorder (ADHD)
 - adults 189
 - antidepressants 52
 - psychostimulants 175, 179–83, 186–90, 193–7
 - substance abuse 251
- atypical antidepressants 43, 47–9, 52–4, 61
- atypical antipsychotics
 - acute mania 92, 94–5, 97–9
 - anxiety 135, 139, 147–8
 - drug interactions 123
 - indications 83, 90
 - pharmacology 87, 90
 - side effects 118–19, 125
- autism 52
- autonomic effects 70
- azopyrones 130

- barbiturates 129, 165–6, 217–18, 231–2
- BDD *see* body dysmorphic disorder
- benzodiazepines
 - anxiety 129–30, 132, 136, 140, 145–6
 - combination therapies 8–10, 12, 15, 58
 - drug interactions 136, 151–2
 - extra-pyramidal symptoms 26
 - mood stabilizers 90, 92–3
 - sedative–hypnotic agents 158–9, 161–4, 166–8, 170–1
 - side effects 150–2, 166–7
 - substance abuse 217, 219, 222, 229–33, 236, 250
 - substance-induced psychoses 22–3
 - withdrawal syndrome 153
- benztropine 10, 26

- beta-blockers
 - anxiety 136, 138, 146–7
 - drug interactions 36
 - extra-pyramidal symptoms 26
 - lithium toxicity 113
 - substance abuse 229
- bethanechol 70
- binge eating 52
- bipolar disorders
 - antipsychotics 19
 - mood stabilizers 101, 106, 126
 - substance abuse 242, 250–1
- body dysmorphic disorder (BDD) 51
- breastfeeding 57
- bromocriptine 29, 202
- bulimia 41, 51
- buprenorphine 219, 234–5, 237, 244–6
- bupropion
 - anxiety 137, 144, 149
 - attention deficit/hyperactivity disorder 181–2
 - combination therapies 66
 - drug interactions 76
 - indications 51, 54
 - initiation of treatment 58
 - maintenance therapy 68
 - pharmacology 43, 47–8
 - side effects 70–5
 - substance abuse 248, 251
- buspiron 130, 134, 136, 138, 146, 148, 250

- calcium channel blockers 203, 206
- carbamazepine
 - anxiety 147
 - drug interactions 76
 - mood stabilizers 84–97, 103–5, 108–11, 115, 117, 120, 124–5

- cardiovascular effects 32–3
- CBT *see* cognitive-behavioral therapy
- central serotonergic syndrome 75
- chloral hydrate 159–60, 163, 168, 232, 251
- chlordiazepoxide 229, 250
- chlorpromazine 2–3, 5, 10, 32–3, 34
- cholinesterase inhibitors 200–1, 205–13
- chronic obstructive pulmonary disease (COPD) 152, 156, 169
- cimetidine 77
- citalopram 44, 46, 48, 133, 137, 141–2
- clomipramine 45, 143, 148
- clonazepam
 - anxiety 132, 134, 138, 145–6
 - mood stabilizers 93
 - substance abuse 236, 246
- clonidine
 - Alzheimer's disease 202
 - attention deficit/hyperactivity disorder 181–2, 194
 - substance abuse 229, 235–6, 246
- clozapine 1, 6, 10–13, 16–17, 19, 24–5, 28–38
- cluster headaches 53
- co-morbidities 57
- cocaine 22–3, 219–20, 241–2, 252
- cognitive enhancers 199–213
 - costs 209
 - dosages 209
 - drug interactions 211–12
 - drug selection 205–6
 - indications 205
 - initiation of treatment 206–7
 - maintenance treatment 207–8
 - pharmacology 199–204
 - side effects 209–11
 - treatment evaluation 208–9
- cognitive-behavioral therapy (CBT) 166
- Conners Teacher/Parent Rating Scales 183–4, 186
- COPD *see* chronic obstructive pulmonary disease
- coumarin 196
- dantrolene 29
- delirium 20
- delirium tremens 224–5
- delusional disorder 20
- dementia 21
- depakene 110
- dermatological effects 115
- desipramine 45, 58, 77, 251
- developmental disorders 21–2
- dextroamphetamine 175–9, 184, 187, 190, 195, 197
- diazepam
 - anxiety 132, 138, 146
 - substance abuse 220–1, 229, 231
- diphenhydramine 26, 157–8
- diphenylbutylpiperidines 20
- disulfiram 238–9, 242
- diuretics 113
- divalproex *see* valproate
- donepezil 200–1, 203–4, 207, 209–11
- dopamine agonists 29, 38
- doxepin 45, 72
- doxylamine 158
- duloxetine
 - antidepressants 43, 47, 49, 53–5, 70, 72, 79
 - anxiety 137, 143
- dysphoric mania 83
- dystonia 25–6

- ecstasy 220–1
- electroconvulsive therapy (ECT)
 acute depression 100, 105
 acute mania 94
 major depression 67
- endocrine effects 30
- epilepsy 72
- EPS *see* extrapyramidal symptoms
- escitalopram 44, 46, 48, 133, 137, 141
- estazolam 163
- estrogens 202
- eszopiclone 160–1, 163–4, 169, 171–2
- ethchlorvynol 232
- ethnicity 56–7
- euphoric mania 83
- extrapyramidal symptoms (EPS)
 1–3, 18, 20, 24–6, 118
- fentanyl 218
- flashbacks 221, 252
- flumazenil 168, 217
- fluoxetine
 antidepressants 42, 44–6, 49–50, 52–4, 66, 72, 79
 anxiety 133, 137, 141–2
 combination therapies 84
 mood stabilizers 84
 substance abuse 249
- fluphenazine decanoate 4, 6, 25
- flurazepam 163
- fluvoxamine 44, 46, 133, 137, 141–2
- gabapentin 87, 135, 138–9, 147, 150
- GAD *see* generalized anxiety disorder
- galantamine 200–1, 204, 207, 209–10, 212
- gastrointestinal effects 34, 73, 115
- gender 56
- generalized anxiety disorder (GAD)
 antidepressants 50
 anxiolytics 130, 136, 139–40, 142–3, 145–6
- Gingko biloba 203
- glutethimide 232
- guanefacine 202
- guanethidine 77, 196
- hallucinogens 220–1, 252
- haloperidol
 antipsychotics 2–6, 10, 20, 22, 25, 27–8, 36
 mood stabilizers 92
 substance abuse 216, 222, 229
- hematological effects 34–5, 75, 116
- hepatic effects 34, 76, 116
- heterocyclic antidepressants 36
- Huntington's disease 22
- hydergine 202, 206
- hydroxyzine
 hydrochloride/pamoate 165
- hypnotics *see* sedative–hypnotic agents
- iloperidone 16, 24
- imipramine 41–2, 45, 58, 143
- insomnia 194
see also sedative–hypnotic agents
- intoxication syndromes 215–22
- iproniazid 41
- isocarboxazid 45
- Korsakoff's amnesic syndrome 230

- lamotrigine
 - anxiety 147
 - mood stabilizers 84–7, 89, 99–103, 105, 109, 120–7
- leukopenia 34–5
- levodopa 23, 38
- lithium
 - acute depression 99–108
 - acute mania 90–6
 - antidepressant augmentation 63–4
 - costs 110
 - drug interactions 119–20, 122
 - indications 83–4, 90
 - pharmacology 85–8
 - side effects 111–16, 124
 - substance abuse 242
- lorazepam
 - anxiety 134, 138, 146
 - mood stabilizers 93–4
 - substance abuse 216, 218, 222, 229
- loxapine 2
- lysergic acid diethylamide (LSD) 220–1, 252

- major depression 19–20, 53, 55–76
- MAOIs *see* monoamine oxidase inhibitors
- maprotiline 45
- MDMA 220–1
- memantine 202, 204–5, 207–9, 211–12
- mental retardation 21–2, 180
- mepheridine 78, 218
- meprobamate 129, 232
- mescaline 220–1
- metabolic effects 31–2
- methadone 233, 237, 242–4
- methamphetamine 22–3, 3, 4-methylenedioxy-N-methylamphetamine (MDMA) 220–1
- methylphenidates (MPH) 77, 175–81, 184, 187–91, 195–6
- methyprylon 232
- migraines 53
- milnacipran 43
- mirtazapine
 - antidepressants 43–4, 47, 49–50, 53, 79
 - anxiety 133–4, 137, 144, 149
 - sedative–hypnotic agents 165
- mixed episodes 83
- mixed serotonin
 - antagonist/reuptake inhibitors 43, 47, 49, 61, 78
- mixed serotonin/noradrenaline
 - antagonists 43–4, 47, 49, 61, 78
- moclobamide 144
- modafinil 182
- monoamine oxidase inhibitors (MAOIs)
 - acute depression 102
 - anxiety 129, 132, 137, 140, 144, 149
 - drug interactions 76
 - drug selection 56, 58–9, 62, 66, 69, 75
 - indications 50–1, 54
 - pharmacology 41–2, 44–5
 - side effects 149
- mood stabilizers 83–127
 - acute depression 99–109
 - acute mania 90–9
 - anxiolytics 93–4
 - breakthrough episodes 103–4
 - costs 110–11

- dosages 94–9, 102–3, 107
- drug interactions 119–23
- drug selection 90–111
- indications 83–5, 90
- initiation of treatment 94–9, 102–3
- maintenance therapy 104–9
- pharmacology 85–90
- pregnancy 117, 124–6
- rapid cycling 83, 110
- side effects 111–19
- steroid-induced psychosis 23
- MPH *see* methylphenidate
- naloxone 218–19, 244–5
- naltrexone 236, 239–41, 246–7
- narcolepsy 190
- narcotics 78
- nefazodone
 - antidepressants 43, 47, 49–50, 53, 75
 - anxiety 133–4, 137, 144, 149–50
- neuroleptic malignant syndrome (NMS) 29–30
- neuroleptics *see* antipsychotics
- neurologic disease 83
- neurologic effects 72–3
- neurotrophic factors 202
- nicergoline 202
- nicotine 38, 247–8, 252
- NMS *see* neuroleptic malignant syndrome
- non-steroidal anti-inflammatory drugs (NSAIDs) 203, 235
- norepinephrine reuptake inhibitors (NRIs) 43
- nortriptyline 45, 56, 58, 72
- NRIs *see* norepinephrine reuptake inhibitors
- NSAIDs *see* non-steroidal anti-inflammatory drugs
- obesity, antidepressants 52
- obsessive–compulsive disorder (OCD)
 - antidepressants 41, 50
 - anxiolytics 131, 140, 142–6, 148
- oestrogens 202
- olanzapine
 - anxiety 135, 138, 147
 - bipolar disorders 19
 - combination therapies 84
 - dementia 21
 - dosages 6, 8, 11
 - drug interactions 36–8
 - mood stabilizers 84, 87, 92, 98, 101, 105, 119
 - schizophrenia 16–19
 - side effects 27–32, 34–5, 119
- opiates 218–19, 233–7, 242–7, 252
- overdose syndromes 215, 217, 218
- oxcarbazepine 85, 118
- oxiracetam 202
- panic disorder (PD) 41, 50, 130, 139–48
- Parkinsonism 25–6
- Parkinson's disease 23
- paroxetine
 - antidepressants 44–6, 48, 51, 57, 66, 70, 78
 - anxiety 133, 137, 141–2, 150
- PCP *see* phencyclidine
- PD *see* panic disorder
- pemoline 180
- pentazocine 218
- perphenazine 5
- phencyclidine (PCP) 22–3, 221–2
- phenelzine 45
- phenobarbital 78, 231–3
- phenylbutazone 197

- physostigmine 200
 pilocarpine 70
 pimozone 22
 piracetam 202
 PMDD *see* premenstrual
 dysphoria
 polacrilex 248
 posttraumatic stress disorder
 (PTSD) 41, 50–1, 131,
 141–8
 pregabalin 135, 139
 pregnancy
 antidepressants 57
 antipsychotics 38–9
 anxiolytics 152
 mood stabilizers 117, 124–6
 premenstrual dysphoria
 (PMDD) 51–2
 propoxyphene 218
 propranolol 113, 146
 protriptyline 45, 53
 psilocybin 220–1
 psychiatric disorders 248–51
 psychoeducation 131
 psychosis 19–20, 21, 194
 see also antipsychotics
 psychostimulants 175–98
 alternative preparations
 189–90
 antidepressant augmentation
 63–4
 antipsychotics 22–3
 attention deficit/hyperactivity
 disorder 175, 179–83,
 186–90, 194–7
 contraindications 180
 costs 191–2
 dosages 183–5, 191–2
 drug interactions 196–7
 drug selection 180–3
 indications 180–1, 193
 initiation of treatment 183–5
 maintenance treatment 185,
 187
 narcolepsy 190
 pharmacology 175–80
 resistance to treatment
 187–8
 side effects 193–6
 substance abuse 219–20
 treatment evaluation 185–6
 psychotherapy 65–6, 105
 PTSD *see* posttraumatic stress
 disorder
 pyrazolopyrimidine indiplon
 159

 quazepam 163
 quetiapine
 antipsychotics 4–6, 11, 16,
 19–20, 24–5, 29–32,
 36–7
 anxiety 135, 147
 mood stabilizers 84, 87, 92,
 98–103, 111, 127

 racial factors 56–7
 ramelteon 161, 163–4, 169
 rapid cycling 83, 110
 rapid neuroleptization 10
 reboxetine 43
 relapse 215, 237–48
 restless leg syndrome 53
 risperidone
 antipsychotics 4–6, 8, 11,
 16–18, 20–5, 28–31, 37
 anxiety 135, 138, 147–8
 mood stabilizers 84, 87, 92,
 98, 101
 ritalin 179
 rivastigmine 200–1, 204, 207,
 209–10, 212

 schizoaffective disorder 15
 schizophrenia 1, 4, 7–19,
 249–50
 sedation 35, 52–3

- sedative-hypnotic agents
 - 155–73
 - diagnoses 155–6
 - drug interactions 170–2
 - drug selection 161–6
 - non-prescription 157–8
 - pharmacology 159–61
 - side effects 159, 161, 164–9
 - special precautions 170–2
 - substance abuse 217–18, 229, 230–3
 - treatment implementation 166–7
 - treatment options 156–7
- seizures 35–6, 129
- selective serotonin reuptake inhibitors (SSRIs)
 - anxiety 130, 132–3, 139–42, 148–52
 - drug interactions 36, 78–9
 - drug selection 56–60, 62–3, 66, 68–75
 - indications 50–5
 - pharmacology 42–4, 46, 48–9
 - side effects 149–51
 - substance abuse 249
- selegiline 202–3
- serotonin-norepinephrine reuptake inhibitors (SNRIs)
 - anxiety 130, 132, 142–3, 149
 - drug interactions 76
 - drug selection 61, 66
 - indications 55
 - pharmacology 43, 47, 53
- sertindole 16, 24
- sertraline
 - antidepressants 44, 46, 51–2, 54, 66, 78
 - anxiety 133, 137, 141–2, 148, 150
- sexual effects 30–1, 73–4
- SJS *see* Stevens-Johnson syndrome
- sleep apnea 53, 152, 171
- sleep hygiene techniques 157
- SNRIs *see*
 - serotonin-norepinephrine reuptake inhibitors
- social phobias
 - antidepressants 50–1
 - anxiolytics 131, 139–40, 143
- SSRIs *see* selective serotonin reuptake inhibitors
- steroid-induced psychosis 23
- Stevens-Johnson syndrome (SJS) 102–3
- stimulants *see* psychostimulants
- substance abuse 215–53
 - alcohol 216–17, 223–30, 238–41, 251
 - amphetamines 219–20
 - antipsychotics 22–3
 - anxiolytics 130
 - cocaine 219–20, 241–2, 252
 - comorbidities 215, 242
 - drug interactions 251–2
 - hallucinogens 220–1, 252
 - intoxication syndromes 215–22
 - mood stabilizers 83
 - multiple dependencies 237
 - nicotine 247–8, 252
 - opiates 218–19, 233–7, 242–7, 252
 - overdose syndromes 215, 217, 218
 - phencyclidine 221–2
 - psychiatric disorders 248–51
 - relapse 215, 237–48
- sedative-hypnotic agents 167
- sedative-hypnotics 217–18, 229, 230–3
- special considerations 247
- withdrawal syndromes 215, 218–19, 222–37, 247–8
- suicidality 18–19, 74–5

- tachycardia 33
 tacrine 200–1, 205, 209–11
 tardive dyskinesia (TD) 1, 2,
 20, 24, 26–9
 TCAs *see* tricyclic
 antidepressants
 TD *see* tardive dyskinesia
 tegretol XR 111
 temazepam 163
 thiamine 230
 thioridazine 32
 thyroid hormones 64–5
 tiagabine 135, 147
 topiramate 87, 135, 147–8
torsade de pointes 33
 Tourette's disorder 22, 52
 tranlycypromine 45
 trazodone
 antidepressants 43, 47–9,
 52–4, 58, 72, 74, 79
 anxiety 145
 sedative–hypnotic agents
 164–5
 triazolam 163, 167–8
 tricyclic antidepressants
 (TCAs)
 acute depression 99–100,
 102
 anxiety 129, 131–2, 137, 140,
 143, 149
 attention deficit/hyperactivity
 disorder 181–2, 194
 drug interactions 76–8
 drug selection 56–9, 62, 66,
 69–75
 indications 50–4
 pharmacology 41–5
 sedative–hypnotic agents
 165
 side effects 149
 substance abuse 249
 trileptal 111
 trimipramine 45
 valproate
 anxiety 135, 147
 costs 110–11
 drug interactions 120
 drug selection 91–4
 initiation of treatment 94–7
 maintenance treatment 105,
 108–9
 pharmacology 84–7
 pregnancy 124–5
 side effects 114
 venlafaxine
 antidepressants 43, 47,
 49–50, 55, 72, 79
 anxiety 130, 132–4, 137,
 142–3, 150
 vigabatrin 139
 violent patients 15
 vitamin E 203
 weight gain 73, 116, 119
 weight loss 194
 Wernicke's encephalopathy
 230
 withdrawal syndromes 215,
 218–19, 222–37, 247–8
 zaleplon 160, 163–4, 169, 171–2
 ziprasidone
 antipsychotics 4–6, 8–11, 16,
 24–5, 28, 30–3, 36–7
 anxiety 135, 171–2
 mood stabilizers 84, 87,
 97–8, 111
 zolpidem 160, 163–4, 168–9,
 232
 zotepine 11, 35
 zyprexa 111

